Appropriateness of fecal immunochemical testing utilization for colorectal cancer screening at an academic center
暂无分享,去创建一个
C. Morley | U. Masood | M. Bernshteyn | Laura A. Schad | N. Pavelock | Kuldip Singh | A. Gupta | V. Jasti | U. Murthy
[1] M. Cabana,et al. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. , 2021, JAMA.
[2] A. Jemal,et al. Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.
[3] V. Kushnir,et al. Charlson Comorbidity Index Is a Useful Predictor of Patients Death Prior to Interval Colonoscopy (Poster Presentation) , 2020 .
[4] J. Carethers. Fecal DNA Testing for Colorectal Cancer Screening. , 2020, Annual review of medicine.
[5] E. Mikkelsen,et al. Demographic and comorbidity predictors of adherence to diagnostic colonoscopy in the Danish Colorectal Cancer Screening Program: a nationwide cross-sectional study , 2018, Clinical epidemiology.
[6] David Lieberman,et al. Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer , 2017, The American Journal of Gastroenterology.
[7] David Lieberman,et al. Colorectal cancer screening: Recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer. , 2017, Gastrointestinal endoscopy.
[8] D. Lieberman,et al. Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. , 2017, Gastroenterology.
[9] E. Bradley,et al. American health care paradox-high spending on health care and poor health. , 2016, QJM : monthly journal of the Association of Physicians.
[10] M. Phipps,et al. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. , 2016, JAMA.
[11] Carrie M. Farmer,et al. Comparing VA and Non-VA Quality of Care: A Systematic Review , 2016, Journal of General Internal Medicine.
[12] Robert G Uzzo,et al. Why Summary Comorbidity Measures Such As the Charlson Comorbidity Index and Elixhauser Score Work , 2015, Medical care.
[13] E. Kuipers,et al. Attendance and Yield Over Three Rounds of Population-Based Fecal Immunochemical Test Screening , 2014, The American Journal of Gastroenterology.
[14] R. Steele,et al. The impact of population-based faecal occult blood test screening on colorectal cancer mortality: a matched cohort study , 2012, British Journal of Cancer.
[15] Bing Li,et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. , 2011, American journal of epidemiology.
[16] M. Leshno,et al. A Quantitative Immunochemical Fecal Occult Blood Test for Colorectal Neoplasia , 2007, Annals of Internal Medicine.
[17] D. Fisher,et al. Inappropriate Colorectal Cancer Screening: Findings and Implications , 2005, The American Journal of Gastroenterology.